Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance Novartis (www.Novartis.com) has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999; With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly…